Table 5.

Percent of CIN cases estimated to be attributable to nine specific HPV types & any HPV type in prior US studies

				% of Cases Estimated to be Attributable to Specific HPV types
Year	Author	N	Testing Method	HPV 6	HPV 11	HPV 16	HPV 18	HPV 31	HPV 33	HPV 45	HPV 52	HPV 58	Any HPV type*
CIN 1 30,31,39–41,43
2006	Srodon, M	36	PCR/Biopsy	2.8	2.8	11.1	16.7	5.6	5.6	5.6	2.8	2.8	100.0
2005	Hu, L†	45	PCR/Biopsy			6.4	2.2	3.1	0.0	2.2	12.2	7.2	87.0
2002	Evans, M†	28	PCR/Biopsy	4.5	3.6	7.1	3.6	7.1	3.6	3.6	7.1	0.0	100.0
1998	Aoyama, C	11	PCR/Biopsy	0.0	0.0	27.3	9.1	9.1	9.1				54.5
1998	Quade, B	30	PCR/Biopsy	3.3	3.3	10.0	3.3	6.7	0.0	0.0	0.0	0.0	73.3
1996	Isacson, C	40	PCR/Biopsy	5.0	10.0
Total		190		3.6	4.8	9.9	6.7	5.6	2.7	2.9	6.1	3.0	87.4
CIN 2/3 30,31,39–43
2006	Srodon, M	116	PCR/Biopsy	0.0	0.0	75.0	4.3	5.2	1.7	0.0	0.9	3.4	100.0
2005	Hu, L†	97	PCR/Biopsy			38.9	9.6	11.6	1.0	1.1	5.0	2.6	93.6
2002	Evans, M	22	PCR/Biopsy	0.0	0.0	68.2	4.5	9.1	4.5	4.5	0.0	4.5	100.0
1998	Aoyama, C	21	PCR/Biopsy	0.0	0.0	52.4	0.0	19.0	19.0				95.2
1998	Quade, B	19	PCR/Biopsy	0.0	0.0	52.6	5.3	0.0	15.8	0.0	0.0	0.0	78.9
1996	Isacson, C	11	PCR/Biopsy	0.0	0.0	45.5	0.0	18.2	9.1	0.0	0.0	0.0	100.0
1993	Shroyer, K	13	PCR/Biopsy	0.0	0.0	61.5	0.0						92.3
Total		299		0.0	0.0	58.1	5.5	8.8	4.2	0.8	2.2	2.8	95.9

* As determined by consensus PCR primers sensitive to positivity for at least 10 HPV types.

^† Lesions in these studies containing multiple HPV types were fractionally attributed to individual HPV types as described in the Methods section. Without this method of attribution, original figures for HPV prevalence differing from those reported in the table were as follows: Evans et al., CIN 1 (HPV 6 – 7.1%); Hu et al., CIN 1 (HPV 16 – 8.9%, 31 – 6.7%, 52 – 13.3%, 58 – 11.1%), CIN 2/3 (HPV 16 – 40.2%, 18 – 12.4%, 31 – 13.4%, 45 – 2.1%, 52 – 8.2%, 58 – 6.2%)

CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; PCR = polymerase chain reaction